Neurology Center of New England P.C.
Quick facts
Phase 3 pipeline
- Abobotulinumtoxin A · Neurology
Abobotulinumtoxin A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Neurology Center of New England P.C. portfolio CI brief
- Neurology Center of New England P.C. pipeline updates RSS
Frequently asked questions about Neurology Center of New England P.C.
What is Neurology Center of New England P.C.'s pipeline?
Neurology Center of New England P.C. has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include Abobotulinumtoxin A.
Related
- Sector hub: All tracked pharma companies